Business context and reporting period
The filing is Trovagene, Inc.’s Form 10-K for the fiscal year ended December 31, 2013; it does not identify Cardiff Oncology, Inc. The filing describes Trovagene as a development-stage molecular diagnostics company developing urine-based cell-free nucleic acid tests, with oncology as its principal focus and other potential applications in infectious disease, transplantation, and prenatal genetics.
During 2013, Trovagene made its first urine-based cancer mutation-monitoring test available through its CLIA laboratory and also reported commercial availability of a urine-based high-risk HPV assay. The company had not recognized revenue from its clinical laboratory tests by year-end; reported revenue was primarily royalties and license fees.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $259,246 | $450,404 |
| Operating expenses | $10.95 million | $5.30 million |
| Loss from operations | $10.69 million | $4.85 million |
| Net loss attributable to common stockholders | $11.84 million | $11.60 million |
| Net loss per share, basic and diluted | $0.70 | $0.89 |
| Cash used in operating activities | $7.32 million | $4.93 million |
| Cash and cash equivalents at year-end | $25.84 million | $10.82 million |
| Working capital at year-end | $24.06 million | $10.32 million |
Revenue fell 42%, as 2012 included $150,000 of milestone fees and $125,000 of license fees that were absent in 2013. Royalty income rose to $259,246 from $175,404. Research and development expense more than doubled to $3.95 million, and selling, general and administrative expense rose to $7.00 million, reflecting expanded development and commercialization activities. The company reported no meaningful operating margin; the filing provides no positive operating earnings or product-test revenue.
Financing activities provided $22.98 million in 2013, including $18.83 million in net common-stock proceeds, $3.60 million from warrant exercises, and $515,964 in equipment-line borrowings. Investing activities used $649,284, mainly for capital equipment. At year-end, total debt under the equipment line was $521,164, of which $198,166 was current; the facility allowed up to $1.0 million of borrowing. Contractual obligations totaled approximately $2.60 million, including leases, research agreements, debt, and vendor commitments.
Material changes versus the prior year
- Operating expenses increased by approximately $5.65 million, while revenue declined by approximately $191,000. The net loss attributable to common stockholders increased modestly, by approximately $237,000.
- Cash increased by approximately $15.02 million, mainly because of equity financing and warrant exercises; common shares outstanding increased from 15.48 million to 18.90 million.
- The reported loss from changes in warrant derivative fair value narrowed to $1.08 million from $6.72 million. A 2013 offering removed price-protection features on certain warrants, leading to a $5.42 million reclassification from derivative liabilities to additional paid-in capital.
- Research and development expense increased from $1.92 million to $3.95 million as personnel, laboratory equipment, and clinical collaborations expanded. General and administrative expense increased from $3.38 million to $7.00 million, largely with commercial infrastructure and public-company costs.
Outlook, risks, and unusual items
- Management said existing cash and cash equivalents were expected to fund operations for at least the next 12 months, but the company expected to need additional capital within 12–18 months to develop and commercialize current candidates and sustain operations. Management also stated that current working capital alone would not fund successful development and commercialization.
- The independent auditor’s report expressed substantial doubt about the company’s ability to continue as a going concern because of recurring operating losses and dependence on additional financing. The financial statements were prepared on a going-concern basis.
- Management expected operating cash outflows to continue for several years and planned approximately $800,000 of capital-equipment investment in the following year. Further losses, R&D costs, and commercialization spending were anticipated; the filing gives no revenue or profitability guidance.
- Commercial success depends on clinical validation, physician and patient adoption, reimbursement, regulatory requirements, and the company’s ability to compete and raise capital. LDT regulation could change, and FDA review may be required for some products. The company had not filed an FDA application for its proposed products.
- Clinical evidence was preliminary. The company reported high urine-to-tissue mutation-status concordance in an early MD Anderson study and preliminary correlation between urine BRAF V600E monitoring and treatment response; these findings do not establish broad clinical utility or improved patient outcomes.
- The company disclosed an opposition by an anonymous third party to claims in a European patent covering microRNA detection. It reported no material pending legal proceedings. A potential approximately $40,000 exposure, plus interest and penalties, was disclosed for an inactive subsidiary’s failure to file Form 5471.
- Warrant fair-value changes materially affected reported non-operating results. The valuation relied on Level 3 inputs, and the filing’s reported derivative-related amounts reflect both remeasurement and reclassification effects.
Important facts for investors to verify
- Confirm the issuer and period: this is Trovagene’s FY 2013 10-K, not a Cardiff Oncology filing or a standalone Q4 report.
- Review the audited statements and going-concern disclosure, including cash burn, financing requirements, debt maturities, and the auditor’s substantial-doubt paragraph.
- Track actual revenue from diagnostic testing, royalty agreements, reimbursement, and commercial adoption; no clinical laboratory test revenue had been recognized through year-end.
- Assess whether subsequent clinical studies validate the preliminary results and demonstrate clinical utility, and whether regulatory or reimbursement changes affect commercialization.
- Evaluate dilution and potential equity supply, including outstanding options and warrants and the company’s reliance on equity financing.